anti-integrin alpha5beta1 blocking antibody

Anti-integrin alpha5beta1 blocking antibodies are a class of therapeutic agents designed to inhibit the function of the alpha5beta1 integrin heterodimer, a primary receptor for fibronectin. This integrin is critically involved in mediating angiogenesis, tumor cell proliferation, and fibrotic processes. By blocking the interaction between alpha5beta1 and its ligands, these antibodies inhibit endothelial cell migration and survival, particularly in response to pro-angiogenic factors like VEGF and bFGF. While historically investigated in oncology (most notably with the chimeric antibody volociximab), recent research has expanded their potential application to fibrostenotic diseases such as ulcerative colitis and Crohn's disease, where they may help resolve tissue fibrosis by modulating fibroblast activity and extracellular matrix deposition. Research compounds such as antibody 339.1 have been utilized in murine models to recapitulate the anti-angiogenic and anti-fibrotic effects of clinical-stage candidates.

Other names

anti-integrin alpha5beta1 blocking antibodyalpha5beta1 blocking antibodyalpha-5beta1 blocking antibodyalpha 5beta1 blocking antibodyanti-a5b1 antibodyanti-a-5b1 antibodyanti-a 5b1 antibodya5b1 blocking antibodya-5b1 blocking antibodya 5b1 blocking antibody